Connect Biopharma is trading at $2.60 (+10.17%) alongside broader biotechnology strength, with no new company-specific announcement identified for September 2, 2026.
- Investors appear focused on expected September topline results from the Phase 2 Seabreeze STAT asthma and COPD studies following completed enrollment.
- The move is best attributed to sector momentum rather than a confirmed company-specific catalyst.